Innovations in Protein Kinase Therapies by rgunnam

VIEWS: 4 PAGES: 2

More Info
									Innovations in Protein Kinase Therapies – Significant Proportion of Protein Kinase
Pipeline Contains Small Molecule Drugs That Target Oncology

Oncology Stands as the Leading Indication, Accounting for 92% of the Current Protein
Kinase Pipeline Status

Protein kinase drugs in the pipeline for all indications were analyzed throughout their
development phases, and it was found that oncology has the highest number of pipeline
drugs, accounting for 92% of total indications, followed by central nervous system
accounting for 2%, hematological disorders accounting for 1%, immunology accounting
for 1%, metabolic disorders accounting for 1%, and others accounting for 3%. Others
include indications like cardiovascular, dermatology, gastrointestinal, genetic disorders,
genito urinary system and sex hormones, hormonal disorders, infectious disease,
musculoskeletal, ophthalmology, pharmaceuticals and healthcare, respiratory, toxicology
and women's health.

The majority of these drugs are in Phase II, followed by Phase I, Phase III and
Preclinical. Only 27 molecules are in discovery phase. The pipeline seems to be outsized
when compared to the last few years, and is growing strategically with increased focus on
protein kinases. In particular, the oncology indication gained a lot of attention, and
protein kinases with their specificity took a major stake in oncology pipeline molecules.

More pharmaceutical companies are focusing on the oncology indication because of the
high levels of unmet needs that exist. This is leading to the development of more and
more pipeline drugs targeting protein kinases that could address the needs of the market.

For Sample Pages, please click or add the below link to your browser:
http://www.gbiresearch.com/RequestSamplePages.aspx?ID=Innovations-in-Protein-
Kinase-Therapies-Significant-Proportion-of-Protein-Kinase-Pipeline-Contains-Small-
Molecule-Drugs-That-Target-
Oncology&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

Pfizer takes a major stake of the protein kinase targeting molecule pipeline. It has 127
molecules in pipeline, among which more than 90% of the molecules are targeting
various types of cancer. Many of the compounds are combination drugs which show
interest in the specificity of the disease type. After Pfizer, the next company with a high
number of molecules in the pipeline is Eli Lilly. It has 94 molecules in pipeline, which
again contains a majority of targeting molecules for cancer. Other major companies with
strong protein kinase targeting drug pipelines are GlaxoSmithKline plc,
AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Novartis AG, Exelixis Inc, Boehringer
Ingelheim GmbH, Merck and Takeda Pharmaceutical Company Limited

GBI Research’s new report, “Innovations in Protein Kinase Therapies – Significant
Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target
Oncology”, provides in-depth analysis of innovations in protein kinase therapies in the
current pharmaceutical market. The report analyzes the protein kinase pipelines of
pharmaceutical companies by indication and also according to the phase of clinical trial.
This report includes protein kinase pipeline profiles of the top 10 pharmaceutical
companies based on their pipeline. It gives you a robust idea of the pipeline, innovations
in various indications, new strategies employed for innovation, trends in combination
drugs and protein kinase targets. This report is built using data and information
 ourced from proprietary databases, primary and secondary research and in-house
analysis by GBI Research’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=Innovations-in-Protein-Kinase-Therapies-
Significant-Proportion-of-Protein-Kinase-Pipeline-Contains-Small-Molecule-Drugs-
That-Target-
Oncology&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

Visit our report store: http://www.gbiresearch.com

For more details contact:
pressreleases@gbiresearch.com
North America:        +1 646 395 5477
Europe:               +44 207 753 4299
                      +44 1204 543 533
Asia Pacific:         +91 40 6616 6782

								
To top